9-Ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile
| Title | Journal |
|---|---|
| Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. | Toxicology letters 20180701 |
| 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-((4-methylpiperazin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)phenyl)pyrimidine-2,4-diamine (WY-135), a novel ALK inhibitor, induces cell cycle arrest and apoptosis through inhibiting ALK and its downstream pathways in Karpas299 and H2228 cells. | Chemico-biological interactions 20180325 |
| ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. | Therapeutic advances in medical oncology 20160101 |
| Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer. | Drugs 20150101 |
| Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20141115 |
| Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. | Clinical cancer research : an official journal of the American Association for Cancer Research 20141115 |
| Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. | Cancer letters 20140901 |
| Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802). | Bioorganic & medicinal chemistry 20120201 |
| CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. | Cancer cell 20110517 |
| KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090501 |
| Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. | Nature 20070802 |